A double-blind controlled trial of 'Gaviscon' in patients with symptomatic gastro-oesophageal reflux.
In a double-blind trial in 26 patients with symptomatic gastro-oesophageal reflux, the alginate/effervescent/antacid compound 'Gaviscon' was compared with antacid containing placebo similarly formulated. Retrosternal pain after meals and at night was significantly reduced whilst patients were taking 'Gaviscon' and the beneficial effects lasted for many weeks after discontinuation of the active preparation.
D000464:Alginates / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000517:prevention & control*; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D012824:Silicic Acid / Q000627:therapeutic use
D000464:Alginates; D000863:Antacids; D001639:Bicarbonates; D012824:Silicic Acid; D000536:Aluminum Hydroxide; D008274:Magnesium